Search results: (10000)
News Chronic Thromboembolic Pulmonary Hypertension – Editorial
Belicová M. Chronic Thromboembolic Pulmonary Hypertension in a Regional Hospital. Vnitř Lék 2011; 57(2): 140–146.
News Modern Physical Therapy for Hemophiliacs
Today's physical therapists working with hemophiliacs find themselves in a unique situation - far more effective treatments are available than in past years, leading to a better quality of life. However, it remains necessary to carefully consider what may still have harmful or positive effects on joint health. Dr. Sebastien Lobet from Cliniques universitaires Saint-Luc in Brussels reflected on joint health, sports, and physical therapy in relation to modern treatment for hemophiliacs during the 9th Hemophilia Academy, held online from October 5 to 7.
News Development of Immune Thrombocytopenia as a Result of Past COVID-19 Illness
Immune thrombocytopenia (ITP) developing secondary to COVID-19 is a completely new experience in clinical practice. A brief summary on this topic, describing incidence and response to treatment, was published last year by authors from Cleveland.
News Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients − Expert Consensus
There are currently no clear recommendations regarding dose reduction or discontinuation of thrombopoietin receptor agonists (TPO-RA) in patients with immune thrombocytopenia (ITP). A consensus by British authors offers insights into current clinical practice and the related issues.
News Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
News Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.
News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia
Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.
News Enoxaparin in Weight-Based Dosing for Thromboprophylaxis in Hospitalized Cancer Patients
Cancer patients are at higher risk of developing thromboembolic disease during hospitalization. Currently, there is not enough evidence supporting the efficacy and safety of the standard fixed dose of low molecular weight heparin in individuals at high risk of thromboembolic disease. Therefore, a Phase II clinical study evaluated the efficacy and safety of weight-adjusted dosing in these patients.
News MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?
What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from the broader spectrum of neuromyelitis optica (NMOSD) in Czechia? And which risk factors pertain to this specific population? Data from the ReMuS registry, summarized in an article by Czech authors recently published in the journal Multiple Sclerosis and Related Disorders, revealed this and more. We offer a unique insight into the issue of COVID-19 in these patients in our conditions.
News Clinical Results of the Pinnacle Acetabular System: Data from the UK Joint Replacement Registry
The Pinnacle Acetabular System has been available on the market for nearly two decades. Since then, it has been implanted in numerous healthcare facilities worldwide. Clinical outcomes of the acetabular system were evaluated by analyzing data from the National Joint Replacement Registry of England, Wales, Northern Ireland, and the Isle of Man.
News Does Dosage Frequency Matter for Adherence to Anticholinergic Treatment in Patients with COPD?
A study by Spanish authors compared the adherence of patients with chronic obstructive pulmonary disease (COPD) to anticholinergic treatment administered once every 12 hours and once every 24 hours.
News Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results
Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of patients with multiple sclerosis (MS), inhibits the proliferation of lymphocytes. As a result, fewer lymphocytes that could damage the CNS pass through the blood-brain barrier. The efficacy and safety of teriflunomide in the global population were examined in the multinational randomized double-blind placebo-controlled TOWER study, with an interesting subanalysis published by Chinese authors.
News Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
News Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy are available today. However, there is no clinical data comparing the risk of bleeding associated with physical activity between factor and non-factor treatments. In this situation, one approach is to model possible scenarios and attempt to indirectly compare different modalities of bleeding prevention.
News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations
Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.
News Study COPDGene Redefines Diagnostic Criteria of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease ranks among the top causes of morbidity and mortality worldwide. Current diagnostic criteria for the disease are based exclusively on spirometric examination. Increasing evidence, however, suggests that a significant number of patients show signs of chronic obstructive pulmonary disease without pathological findings on spirometry. The analysis of the COPDGene study thus proposes expanding the diagnostic criteria to include additional parameters.
News Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.
News Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or non-factor treatment, represented in clinical practice by FVIII mimetic antibody emicizumab. However, insights into the direct comparison of effectiveness and economic burden arising from prophylaxis with these modalities are limited, including data from real-world practice. One recently published study therefore attempted to conduct such a retrospective comparison based on data from healthcare-related databases in the USA.
News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.